Abstract:Non-small cell lung cancer (NSCLC) exhibits a high mutational burden. As a result, patients afflicted by this tumor type experience greater responses to immune checkpoint blockade. This is largely due to the ability of T cells to destroy tumor cells on the basis of antigens recognized by their T cell receptor (TCR). However, the lungs are exposed to carcinogens and pathogens which can also trigger a T cell response distinct from cancer. Therefore, a better understanding of the T cell repertoire in the lungs is needed to improve upon the success of current immunotherapies in NSCLC. We obtained peripheral blood, tumors, and adjacent uninvolved lungs from a cohort of 236 early stage NSCLC patients. Whole exome sequencing, RNA microarray, immunohistochemistry (CD3, CD4, CD8, CD57, CD68, FoxP3, CD45RO, GzmB, PD-1, and PD-L1) and T cell repertoire sequencing were performed in NSCLC patients and lungs from organ donors and COPD patients. Antigen specificity was predicted using the Grouping of Lymphocyte Interactions by Paratope Hotspot (GLIPH) algorithm. Single cell TCR and RNA sequencing as well as sequencing of the virome are underway. Clonality was associated with CD8 T cells (r=0.31; p=0.0003), GzmB (r=0.29; p=0.001) and IFN-γ (r=0.52; p<0.0001) production as well as with tumor mutational burden (r=0.19; p=0.015), HLA-B (r=0.29; p=0.0005) and β2-m expression (r=0.20; p=0.018). Patients with classical EGFR mutations exhibited lower T cell clonality (p=0.003) even after adjustment for TMB, highlighting the impact of this driver mutation on the T cell response. Surprisingly, clonality was higher in the adjacent uninvolved lung than tumor (p<0.0001), suggesting an active antigenic response outside the tumor. Comparison of the composition of the T cell repertoire between the uninvolved lung and tumor revealed 57% of the top 100 T cells in the tumor were also found in the adjacent normal lung, highlighting certain parallels in the ongoing antigenic responses. Deeper analysis suggested that shared T cells may have been reactive against mutations shared between the normal lung and tumor (r=0.23, p=0.028) or viruses (p<0.0001). Accordingly, patients with a more reactive T cell repertoire outside the tumor (i.e. bystanders) exhibited shorter disease-free survival (p=0.036) suggesting these responses against shared mutations and/or viruses may detract from the anti-tumor T cell response. Our findings highlight the importance of understanding the specificity of the T cell repertoire in the lungs in patients with NSCLC treated with immunotherapy. As a high proportion of bystander T cells appear to reside in the lungs, their reactivation could contribute to the impaired responses and/or increased toxicity observed in certain patients with NSCLC treated with immunotherapy.

Additional File 4 of Single-cell Transcriptome and Antigen-Immunoglobin Analysis Reveals the Diversity of B Cells in Non-Small Cell Lung Cancer

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Additional File 8 of Single-cell Landscape of Immunocytes in Patients with Extrahepatic Cholangiocarcinoma

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Additional File 4: Table S3. of Comprehensive Analyses of Tumor Immunity: Implications for Cancer Immunotherapy

Supplementary Table 5 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Single-cell Transcriptomics Reveals Tumor-Infiltrating B Cell Function after Neoadjuvant Pembrolizumab and Chemotherapy in Non-Small Cell Lung Cancer.

Additional File 3: Table S2. of Comprehensive Analyses of Tumor Immunity: Implications for Cancer Immunotherapy

Additional File 8 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Single-Cell Transcriptomics of Immune Cells Reveal Diversity and Exhaustion Signatures in Non-Small-Cell Lung Cancer

The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma

Additional File 4 of Intratumoral Heterogeneity As a Predictive Biomarker in Anti-Pd-(l)1 Therapies for Non-Small Cell Lung Cancer

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Additional File 3 of Exploration of Predictive and Prognostic Alternative Splicing Signatures in Lung Adenocarcinoma Using Machine Learning Methods

P1.03-11 Analysis of T-Cell Repertoires in Benign and Malignant Solitary Pulmonary Nodules to Evaluate Tumor Immune Microenviroment

Additional File 3 of Machine Learning and Bioinformatics Analysis Revealed Classification and Potential Treatment Strategy in Stage 3–4 NSCLC Patients

Integrative Analysis of Multi-Omics Data Reveals the Heterogeneity and Signatures of Immune Therapy for Small Cell Lung Cancer.

Additional File 3 of Construction of a Predictive Model for Immunotherapy Efficacy in Lung Squamous Cell Carcinoma Based on the Degree of Tumor-Infiltrating Immune Cells and Molecular Typing

Clinical Relevance of Intratumoural Immune Cell Composition in Non-Small Cell Lung Cancer.

MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer

Additional File 4 of Cancer-associated Fibroblast Infiltration in Gastric Cancer: the Discrepancy in Subtypes Pathways and Immunosuppression